Embracing ICH Q14 Guidelines for Analytical Procedures

In the rapidly evolving field of analytical development, staying abreast of recent regulatory changes is crucial for compliance and innovation. 

This presentation will delve into the latest regulations impacting analytical development typically focusing on ICHQ14, providing a comprehensive overview of the new standards and guidelines that professionals must adhere to.

Furthermore, we will explore the contrasting methodologies between conventional and enhanced approaches in analytical development.

Presenter:  Manu Grover (Business Development Manager – Pharma Markets, Agilent Technologies, Inc.)

Manu Grover holds a postgraduate degree in Pharmacy from the Manipal Academy in India and brings over 21 years of experience in chromatography. He has worked with leading pharmaceutical companies, including Dr. Reddy's, Panacea Biotec, and Ozone Pharmaceuticals, supporting IND, NDA, and ANDA filings.

Throughout his career, Manu has developed and validated analytical methods using HPLC, GC, particle sizing, DSC, pXRD, and LC/MS instruments. He has also successfully filed multiple analytical dossiers for the U.S. and EU markets. In his current role at Agilent, he collaborates closely with the sales team, regulators, and pharmaceutical scientists, providing market insights, tracking industry trends, and sharing expertise on Agilent’s portfolio of columns and supplies.